Inhibitors of mpox VP39 2′-O methyltransferase efficiently inhibit the monkeypox virus

N-Arylsulfonamide-based adenosine analogues to target RNA cap N7-methyltransferase nsp14 of SARS-CoV-2

“…9 By interacting with these MTases and selectively modulating their activities, we might expect to block viral infection, as previously demonstrated with SAH analogues and derivatives on various viruses. 5,10–14 Spurred by the recent SARS-CoV-2 pandemic, the N 7-MTase nsp14 is an emerging target of great interest for inhibitor development, and over the past three years numerous groups worldwide have proposed original active compounds against this enzyme. 15–28 Most nsp14 inhibitors have been designed as SAM-derived compounds, 17,19,21,23–26,28 but high-throughput screening of large libraries 18,20 or a structure-based docking approach on large libraries 27 have also lead to non-SAM-like inhibitors of nsp14.…”